Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy

BACKGROUND: 25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a decrease in left ventricular ejection fraction. The aim of this study is to creat...

Descripción completa

Detalles Bibliográficos
Autores principales: Otchere, Prince, Adekoya, Olusola, Governor, Samuel B., Vuppuluri, Naveen, Prabhakar, Akruti, Pak, Stella, Oppong-Nkrumah, Oduro, Cook, Francis, Bohinc, Rudy, Aune, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197831/
https://www.ncbi.nlm.nih.gov/pubmed/37208775
http://dx.doi.org/10.1186/s40959-023-00177-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197831/
https://www.ncbi.nlm.nih.gov/pubmed/37208775
http://dx.doi.org/10.1186/s40959-023-00177-y

Ejemplares similares